Medicus Pharma Ltd. Common Stock (MDCX) NASDAQ
Currency In USD
AD
- General
- Statistics
- Historical Data
- Profile
- Financials
AD
Currency In USD
| Previous Close | 0.26 |
| Open | 0.2 |
| Day High | 0.21 |
| Day Low | 0.15 |
| 52-Week High | 3.05 |
| 52-Week Low | 0.15 |
| Volume | 93.05M |
| Average Volume | 1.6M |
| Market Cap | 3.82M |
| PE | -0.09 |
| EPS | -1.99 |
| Moving Average 50 Days | 0.34 |
| Moving Average 200 Days | 0.8 |
| Change | -0.09 |
Medicus Pharma Provides Interpretation of Positive Phase 2 SkinJect™ Dataset
GlobeNewswire Inc.
Mar 09, 2026 11:30 AM GMT
The Company Reported 73% Clinical Clearance in the 200-µg cohort at Day 57PHILADELPHIA, March 09, 2026 (GLOBE NEWSWIRE) -- Medicus Pharma Ltd. (NASDAQ: MDCX) ("Medicus" or the "Company"), a biotech/life sciences company focused on advancing the cli
Medicus Pharma Reports Positive Phase 2 SKNJCT-003 Topline Data Observing 73% Clinical Clearance and 40% Histological Clearance (CR) at Day 57 in 200μg Cohort
GlobeNewswire Inc.
Mar 05, 2026 12:30 PM GMT
The Company is expected to finalize the Clinical Study Report (CSR) in Q2 2026 to support planned end of Phase 2 (EOP2) meeting with the FDAPHILADELPHIA, March 05, 2026 (GLOBE NEWSWIRE) -- Medicus Pharma Ltd. (NASDAQ: MDCX) ("Medicus" or the "Compa
Medicus Pharma To Participate in the 38th Annual Roth Conference
GlobeNewswire Inc.
Mar 03, 2026 12:30 PM GMT
Company Exec. Chairman & CEO in a fireside chat is expected to highlight the role of Skinject in an autosomal dominant rare disease, AI-enabled drug development strategy and partnering readinessPHILADELPHIA, March 03, 2026 (GLOBE NEWSWIRE) -- Medic